Last reviewed · How we verify
Hydroxizine — Competitive Intelligence Brief
phase 1
5-hydroxytryptamine receptor 2A, Cytochrome P450 2D6, D(2) dopamine receptor
Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Hydroxizine (Hydroxizine) — King Faisal Specialist Hospital & Research Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Hydroxizine TARGET | Hydroxizine | King Faisal Specialist Hospital & Research Center | phase 1 | 5-hydroxytryptamine receptor 2A, Cytochrome P450 2D6, D(2) dopamine receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Hydroxizine CI watch — RSS
- Hydroxizine CI watch — Atom
- Hydroxizine CI watch — JSON
- Hydroxizine alone — RSS
Cite this brief
Drug Landscape (2026). Hydroxizine — Competitive Intelligence Brief. https://druglandscape.com/ci/hydroxizine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing